SCHEMBL5409563

SCHEMBL5409563

COc1cccc(CNC(=O)c2ccccc2-c2ccccc2C(=O)N(CCC(=O)O)CCc2ccncc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.61
ROCK2 O75116 7/20 0.50
ROCK1 Q13464 6/20 0.50
HPGD P15428 2/20 0.50
PRKACA P17612 2/20 0.50
PRKX P51817 2/20 0.50
PRKCQ Q04759 2/20 0.50
ALDH1A1 P00352 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
GSK3A P49840 1/20 0.50
GSK3B P49841 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
KDM4E B2RXH2 1/20 0.50
USP2 O75604 1/20 0.50
APEX1 P27695 1/20 0.49
AURKA O14965 1/20 0.48
GRK5 P34947 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401607 0.97 RAB9A (0.58) RAB9AROCK2ROCK1HPGDPRKACA
SCHEMBL5399552 0.95 RAB9A (0.67) RAB9AHPGDALDH1A1KMT2AKDM4E
SCHEMBL5398996 0.93 RAB9A (0.67) RAB9AHPGDALDH1A1KMT2AKDM4E
SCHEMBL5406178 0.92 RAB9A (0.64) RAB9AHPGDALDH1A1KMT2AKDM4E
SCHEMBL5394126 0.92 RAB9A (0.59) RAB9AROCK1HPGDPRKACAPRKX
SCHEMBL5409010 0.91 RAB9A (0.65) RAB9AHPGDALDH1A1KMT2AKDM4E
SCHEMBL5394900 0.91 RAB9A (0.64) RAB9AHPGDALDH1A1KMT2AKDM4E
SCHEMBL5411828 0.90 RAB9A (0.62) RAB9AHPGDALDH1A1KMT2AKDM4E
SCHEMBL5392894 0.90 POLB (0.50) RAB9AHPGDALDH1A1KMT2ACYP3A4
SCHEMBL5405922 0.90 RAB9A (0.66) RAB9AHPGDALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB RAB9A 3132/4885ROCK2 4395/4885ROCK1 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.